Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Amortization of Deferred Charges (2023 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 3 years of Amortization of Deferred Charges data on record, last reported at $6.8 million in Q2 2025.

  • For Q2 2025, Amortization of Deferred Charges rose 12.68% year-over-year to $6.8 million; the TTM value through May 2025 reached $20.2 million, up 31.12%, while the annual FY2025 figure was $20.2 million, 31.12% up from the prior year.
  • Amortization of Deferred Charges reached $6.8 million in Q2 2025 per LFCR's latest filing, down from $12.6 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $12.6 million in Q1 2025 and bottomed at -$3.9 million in Q4 2024.
  • Average Amortization of Deferred Charges over 3 years is $4.5 million, with a median of $4.0 million recorded in 2024.
  • Peak YoY movement for Amortization of Deferred Charges: tumbled 224.53% in 2024, then soared 287.68% in 2025.
  • A 3-year view of Amortization of Deferred Charges shows it stood at $3.1 million in 2023, then crashed by 224.53% to -$3.9 million in 2024, then skyrocketed by 274.6% to $6.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $6.8 million in Q2 2025, $12.6 million in Q1 2025, and -$3.9 million in Q4 2024.